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Abstract: N-3 polyunsaturated fatty acids such as docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) have protective effects against atherosclerosis. Monocyte
chemotactic protein (MCP)-1 is a major inflammatory mediator in the progression of
atherosclerosis. However, little is known about the regulation of MCP-1 by DHA and EPA
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in vessels and vascular smooth muscle cells (VSMCs). In this study, we compared the
effect of DHA and EPA on the expression of Mcp-1 in rat arterial strips and rat VSMCs.
DHA, but not EPA, suppressed Mcp-1 expression in arterial strips. Furthermore, DHA
generated 4-hydroxy hexenal (4-HHE), an end product of n-3 polyunsaturated fatty acids
(PUFAs), in arterial strips as measured by liquid chromatography-tandem mass spectrometry.
In addition, 4-HHE treatment suppressed Mcp-1 expression in arterial strips, suggesting
4-HHE derived from DHA may be involved in the mechanism of this phenomenon.
In contrast, Mcp-1 expression was stimulated by DHA, EPA and 4-HHE through p38
kinase and the Keap1-Nuclear factor erythroid-derived 2-like 2 (Nrf2) pathway in VSMCs.
In conclusion, there is a dual effect of n-3 PUFAs on the regulation of Mcp-1 expression.
Further study is necessary to elucidate the pathological role of this phenomenon.
Keywords: monocyte chemotactic protein 1; 4-hydroxy hexenal; docosahexaenoic acid;
eicosapentaenoic acid
1. Introduction
Atherosclerosis is characterized by accumulation of oxidized fat, thickening of vessel walls by
collagens secreted by proliferating vascular smooth muscle cells, and macrophage filtration [1]. There
are several steps in the progression of atherosclerosis: (1) endothelial dysfunction, (2) migration of
leukocytes and smooth muscle cells into the vessel wall, (3) foam cell formation, and (4) degradation
of extracellular matrix. Epidemiologically, fish consumption negatively correlates with cardiovascular
events, suggesting beneficial effects of n-3 polyunsaturated fatty acids (PUFA) [2,3]. Other clinical
studies have indicated that n-3 PUFAs improved the carotid intima-media thickness and endothelial
function [4,5], suggesting that n-3 PUFAs attenuate atherosclerosis by decreasing migration of
leukocytes and proliferation of smooth muscle cells. This is supported by animal experiments that
showed n-3 PUFAs attenuated VCAM-1 expression and macrophage filtration [6]. N-3 PUFAs mainly
consist of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). However, the difference
between EPA and DHA in terms of their anti-atherosclerotic effect is still unclear.
Monocyte chemotactic protein (MCP)-1/chemokine (C-C motif) ligand 2 (CCL2) is expressed in
inflammatory cells and stromal cells such as endothelial and smooth muscle cells, and its expression is
regulated by proinflammatory stimuli and tissue injury. MCP-1 is regulated both by the nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) pathway and stress-activated kinases including
p38, ERK and JNK [7]. There are several potential mechanisms that explain the anti-inflammatory
effect of EPA and DHA. A recent report revealed that G-protein coupled receptor 120 (GPR120) is a
receptor for DHA that mediates anti-inflammatory and insulin-sensitizing effects in rodents [8]. Other
reports have suggested that resolvins and protectins—which are derived from EPA and DHA—are
mediators of the anti-inflammatory effects [9]. We have recently reported that 4-hydroxy hexenal
(4-HHE)—an end product of n-3 PUFA peroxidation—activates the nuclear factor erythroid 2-related
factor 2 (Nrf2)-Kelch-like ECH-associated protein 1 (Keap1) pathway in human umbilical vein
endothelial cells (HUVECs), contributing to endothelial function and antioxidative activity [10,11].
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Nrf2 is a redox-sensitive master regulatory transcription factor regulated by Keap1. Electrophiles,
shear stress, and reactive oxygen species (ROS) stimulate modification of the cysteine residues of
Keap1, which allows its translocation to the nucleus. Nrf2 induces antioxidant enzymes such as heme
oxygenase-1 (Hmox1) through the antioxidant response element (ARE) consensus sequence [12,13].
The 4-HHE induces Nrf2-mediated Hmox1 expression in multiple organs [14,15]. In addition, it has also
been reported that DHA induces Nrf2-mediated Hmox1 expression in human vascular smooth muscle
cells (VSMCs) isolated from small pulmonary artery or endothelial cells [16,17].
Therefore, we examined the regulation of MCP-1 by DHA and EPA in arterial strips and VSMCs.
Furthermore, we measured the 4-HHE content by a liquid chromatography-tandem mass spectrometry
(LC-MS/MS) and tested its role in these tissues.
2. Methods
2.1. Reagents
Dulbecco’s Modified Eagle’s Medium (DMEM) and fetal bovine serum (FBS) were obtained from
Life Technologies (Grand Island, NY, USA). EPA, DHA, and 4-HHE were purchased from Cayman
(Ann Arbor, MI, USA). The MTT assay kit, anti-β-actin (A5316) antibody and N-acetyl-L-cysteine were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Fatty acid-free bovine serum albumin (BSA)
was purchased from Nacalai Tesque (Kyoto, Japan). Anti-p38 (#9112), anti-phospho-p38 (#9211),
anti-ERK1/2 (#9102), anti-phospho-ERK1/2 (#9106), anti-JNK (#9252), anti-phospho-JNK (#9251),
and anti-caspase-3 (#9661) antibodies were purchased from Cell Signaling (Danvers, MA, USA).
Horseradish peroxidase-linked anti-mouse and anti-rabbit antibodies were purchased from Amersham
Biosciences Corp. (Piscataway, NJ, USA). 2171-Dichlorodihydrofluorescein diacetate (H2DCFDA) and
small interfering RNA (SiRNA) reagents were purchased from Life Technologies (Tokyo, Japan).
SB203580, PD98059 and SP600125 were purchased from Calbiochem (Cambridge, UK).
2.2. Animals and Experimental Procedures
All animal experimentation was approved by the committee for Animal Research of Shiga University
of Medical Science (No. 2014-4-8, 7 May 2014). The experimental procedure for artery strips was
performed as previously reported [18]. Briefly, eight-week-old male Sprague-Dawley rats (Japan SLC,
Shizuoka, Japan) were housed in an environmentally controlled room with a 12 h light/dark cycle and
free access to food and water. Rats were fed a regular diet (Dyets Inc., Bethlehem, PA, USA) for
12 weeks. After 12 h of fasting, rats were sacrificed by bleeding from the abdominal aorta under
deep anesthesia. The thoracic aorta was dissected, excised, and cut into strips with special care
being taken to preserve the endothelium. The strips were then fixed vertically between hooks in a
muscle bath (10-mL capacity) containing modified Ringer-Locke solution bubbled with a gas mixture
of 95% O2 and 5% CO2, pH 7.4 at 37 ˘ 0.3 ˝C. After treatment with DHA, EPA or 4-HHE for
6 h, the arterial strips were immediately freeze-clamped by liquid nitrogen, and stored at ´80 ˝C.
For lipid extraction, the frozen tissues were pulverized into a fine powder using a Cryo Press disruptor
(Microtec Co., Ltd., Chiba, Japan). This fine powder was weighed on an ME235 electronic balance
(Sartorius AG, Göttingen, Germany), homogenized in 490 µL of chloroform/methanol (1:1, v/v) and
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10 µL of dibutylhydroxytoluene solution (10 mg/mL in ethanol), and incubated at 36 ˝C for 1 h [19].
The resulting solution was used for measuring the 4-HHE content.
2.3. Cell Culture
VSMCs were isolated from the aortas of male Sprague-Dawley rats (150–200 g) by enzymatic
digestion as previously described [20]. Briefly, cells were maintained in DMEM supplemented with
10% FBS, and used between the 4th–12th passages except for primary cells, showing a dramatic growth
rate because of transformation. Cells were grown to confluence in 12-well plates, and cell growth was
arrested for 24 h in DMEM supplemented with 1% FBS before the real-time quantitative polymerase
chain reaction (RT-qPCR) experiments.
2.4. Fatty Acid Treatment
DHA or EPA was administered as a complex with fatty acid-free BSA as previously described [15].
Briefly, 0.3 mM DHA or EPA was dissolved in ethanol (2.5 mL), and gradually solubilized in an
8.4% BSA solution (14.3 mL) at 37 ˝C. The 4-HHE was dissolved in dimethyl sulfoxide and then in
serum-containing medium.
2.5. Messenger RNA (mRNA) Extraction and Real-Time RT-qPCR Analysis
Total RNA was extracted from cells and tissues using a Total RNA Mini Kit (Bio-Rad, Hercules,
CA, USA). Single-stranded cDNA was synthesized from 1.5 µg of total RNA using the Prime Script
RT Reagent Kit (Takara Bio, Shiga, Japan), and endogenous genomic DNA was degraded by DNase I
(Life Technologies, CA, USA). RT-qPCR experiments were carried out with SYBR Green PCR master
mix (Life Technologies, CA, USA) and the ABI 7500 Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). All the quantitative data were normalized against the expression levels of
18S rRNA (18S). RT-qPCR conditions were 95 ˝C for 10 min, followed by 40 cycles of 95 ˝C for
15 s and 60 ˝C for 1 min. The primers for the RT-qPCR are listed in Table 1.
Table 1. Candidate genes, primer sequences and accession numbers.
Forward Primer Reverse Primer Accession Number
Mcp-1 GCTGCTACTCATTCACTGGCAA TGCTGCTGGTGATTCTCTTGTA NM_031530.1
Hmox-1 TCTATCGTGCTCGCATGAAC AAGGCGGTCTTAGCCTCTTC NM_012580.2
Nrf2 GGAGCAATTCAACGAAGCTC ACAGTTCTGAGCGGCAACTT NM_031789.2
18S TTCCGATAACGAACGAGACTCT TGGCTGAACGCCACTTGTC NR_046237.1
2.6. Quantitative Analysis of 4-HHE in Biological Samples
The 4-HHE in aorta and VSMCs was quantitatively analyzed using LC-MS/MS procedure as
described previously [15,21]. Briefly, a standard solution of 4-HHE (Cayman Chemical Co., Ann Arbor,
MI, USA) was used for the calibration curve. Solid-phase extraction was done using a mixed-mode
anion exchange solid-phase extraction (SPE) cartridge (Oasis MAX, Waters, Milford, MA, USA).
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An ACQUITY CSH C18 column (Waters) was used for separating 4-HHE. Electrospray ionization (ESI)
was carried out with API4000 operating in the positive ionization and SRM mode. The SRM transitions
for CHD-derivatized 4-HHE were m/z 284-216.
2.7. MTT Assay for Cell Viability
Rat VSMCs were seeded on 24-well plates. To determine the cell toxicity of DHA, EPA and 4-HHE,
confluent cells were exposed to these reagents for 24 h, and then washed with phosphate-buffered saline
(PBS). Cell viability was determined by the conventional MTT assay as previously described [11].
The absorbance of BSA-treated cells was used as the control.
2.8. Reactive Oxygen Species (ROS) Measurement Assay
Intracellular ROS production was determined using the fluorescent probe H2DCFDA in VSMCs
incubated with 20 µM H2DCFDA for 20 min as previously described [11]. Following washing with
PBS, cells were incubated with 50 µM DHA or 50 µM EPA. The fluorescence emitted from the cells
was recorded immediately at 492 nm (excitation) and 525 nm (emission) using a fluorescent microplate
reader (Tecan, Männedorf, Switzerland) over a 2-h period.
2.9. Western Blot Analysis
Total protein samples from VSMCs were prepared as previously descried [11], and were resolved by
SDS-PAGE before being transferred to PVDF membranes. Membranes were incubated with antibodies
against p38, ERK, JNK, their phosphorylated forms, caspase-3, or β-actin. Blots were then incubated
with horseradish peroxidase-linked second antibody (Amersham, Buckinghamshire, UK), followed by
chemiluminescence detection (PerkinElmer, Waltham, MA, USA).
2.10. Statistical Analysis
Data are presented as mean ˘ SE, unless otherwise stated. Differences between more than three groups
were analyzed by Tukey–Kramer test. When two groups were compared, differences were analyzed by
two-tailed Student’s t-test. P < 0.05 was considered statistically significant.
3. Results
3.1. Docosahexaenoic Acid (DHA)—Though Not Eicosapentaenoic Acid (EPA)—Inhibits Mcp-1 mRNA
Expression in Rat Aorta
To explore the direct effects of EPA and DHA on vessels, we examined the expression of Mcp-1
mRNA in rat arterial strips. DHA (50–100 µM) but not EPA (50–100 µM) almost completely inhibited
the expression of Mcp-1 mRNA compared with BSA (Figure 1A). In contrast, DHA increased the
expression of heme oxygenase 1 (Hmox-1) (Figure 1B), which is a known antioxidative gene in vessels.
EPA also increased the expression of Hmox-1, but to a lesser extent than DHA did (Figure 1B). Because
Hmox-1 is a target gene of the Keap1-Nrf2 pathway, we measured the lipid peroxidation product levels
in rat arterial strips by LC-MS/MS with or without n-3 PUFA incubation. We found that DHA but not
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EPA increased the tissue 4-HHE content, whereas it did not change the content of 4-hydroxy 2-noneral
(4-HNE), a lipid peroxidation product derived from n-6 PUFA (Figure 1C). To test the role of 4-HHE,
we exposed the arterial strips to 4-HHE and found that it inhibited the expression of Mcp-1 (Figure 1D)
and increased that of Hmox-1 (Figure 1E) in rat aortic strips, suggesting that DHA regulates Mcp-1 and
Hmox-1 expression through 4-HHE.
Nutrients 2015, 7 6 
 
 
EPA increased the tissue 4-HHE content, whereas it did not change the content of 4-hydroxy 2-noneral 
(4-HNE), a lipid peroxidation product derived from n-6 PUFA (Figure 1C). To test the role of 4-HHE, 
we exposed the arterial strips to 4-HHE and found that it inhibited the expression of Mcp-1 (Figure 1D) 
and increased that of Hmox-1 (Figure 1E) in rat aortic strips, suggesting that DHA regulates Mcp-1 and 
Hmox-1 expression through 4-HHE. 
 
Figure 1. Docosahexaenoic acid (DHA)-derived DHA generated 4-hydroxy hexenal  
(4-HHE) inhibits the expression of Mcp-1 Messenger RNA (mRNA), but induces heme 
oxygenase 1 (Hmox-1) mRNA in rat aorta. Rat arterial strips were treated with bovine serum 
albumin (BSA), DHA (50–100 μM), EPA (50–100 μM) or 4-HHE (25–50 μM) for 6 h under 
ex vivo conditions. (A, B) Relative mRNA expression of Mcp-1 (A) and Hmox-1 (B) in 
arterial strips was quantitated using the real-time quantitative polymerase chain reaction 
(RT-qPCR). Results were normalized against 18S rRNA and expressed as fold increase over 
control. (C) 4-HHE and 4-HNE content were measured by a liquid chromatography-tandem 
mass spectrometry (LC-MS/MS). (D, E) Relative mRNA expression of Mcp-1 (D) and 
Hmox-1 (E) in arterial strips was quantitated using RT-qPCR. Results were normalized as 
above. Results are expressed as mean ± SE of 4–8 animals (n = 3–22; A, B, D, E), or a single 
experiment (n = 3; C). * P < 0.05, *** P < 0.001, compared with BSA control. NS, no 
significant difference. 
Figure 1. Docosahexaenoic acid (DHA)-derived DHA generated 4-hydroxy hexenal
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3.2. Paradoxical Increase in Mcp-1 by DHA, EPA and 4-HHE in VSMCs
In contrast to the results observed for arterial strips, DHA, EPA and 4-HHE increased the expression
of Mcp-1 mRNA in a dose-dependent manner in rat VSMCs (Figure 2A). To clarify the differences
in Mcp-1 responses between rat arterial strips and VSMCs (Passage 4–12), we performed the same
experiment using primary VSMCs (Passage 1). Similar to VSMCs (Passage 4–12), DHA, EPA, and
4-HHE increased the expression of Mcp-1 in primary VSMCs (Figure 2B). Similar to rat arterial strips,
DHA (50 µM), but not EPA (50 µM), increased the content of 4-HHE in VSMCs (Figure 2C), whereas
it did not change the 4-HNE content.
Because n-3 PUFAs are known activators of the mitogen-activated protein kinase (MAPK) family, we
assessed the phosphorylation levels of p38 kinase, ERK and JNK. DHA, EPA and 4-HHE increased the
phosphorylation levels of p38, ERK and JNK (Figure 2D). To understand the effect of the MAPK family
on the Mcp-1 expression, we tested the effect of MAPK inhibitors on DHA-, EPA- or 4-HHE-induced
Mcp-1 expression. Pre-incubation with the p38 kinase inhibitor SB203580 completely suppressed the
induction of Mcp-1 expression (Figure 2E). The ERK inhibitor PD98059 had a partial inhibitory effect
on Mcp-1 expression, whereas the JNK inhibitor SP600125 did not (Figure 2E).
3.3. 4-HHE Derived from DHA Induces Mcp-1 Expression through the Nrf2 Pathway in Human
Vascular Smooth Muscle Cells (VSMCs)
To evaluate the oxidative stress induced by DHA and 4-HHE, we used N-acetyl-L-cysteine (NAC),
a known antioxidant that mimics glutathione. Pretreatment with NAC (10 mM) completely inhibited
the DHA-, EPA- and 4-HHE-induced Mcp-1 expression (Figure 3A). Furthermore, DHA and EPA
increased ROS production measured by H2DCFDA (Figure 3B). NAC pretreatment completely inhibited
the DHA-induced ROS production in VSMCs (Figure 3B), supporting the role of oxidative stress in the
DHA-induced Mcp-1 expression.
To evaluate Nrf2 activation by DHA and 4-HHE, we examined the mRNA expression of Hmox1,
a target of Nrf2, in VSMCs. We found that DHA and 4-HHE stimulated the expression of Hmox1 mRNA
in VSMCs, and that NAC inhibited the DHA- and 4-HHE-induced Hmox-1 expression (Figure 3C).
As expected, the 4-HHE-induced Mcp-1 expression was decreased by siRNA against Nrf2 (Figure 3D,E).
3.4. DHA Induces Apoptosis of VSMCs through 4-HHE
To test the toxicity of n-3 PUFA in VSMCs, VSMCs were incubated for 24 h with DHA, EPA or
4-HHE at a higher but physiological concentration, followed by measurement of cell viability by the
MTT assay. DHA and 4-HHE only decreased cell viability at a high concentration (150 µM) compared
with the BSA control (Figure 4A). In contrast, EPA did not decrease the cell viability of VSMCs
(Figure 4A).
Apoptosis is a known downstream process of ROS production. Increased cleaved caspase-3
expression measured by Western blot analysis indicated that the cell toxicity of DHA and 4-HHE was
caused by the induction of apoptosis (Figure 4B).
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Figure 2. DHA, EPA, and 4-HHE induce Mcp-1 expression through the p38
mitogen-activated protein kinase (MAPK) pathway in VSMCs. VSMCs (Passage 4–12)
were treated with the indicated reagent for 6 h (A). (B) Primary vessels and vascular smooth
muscle cells (VSMCs) (Passage 1) were treated with BSA, DHA (50 µM), EPA (50 µM)
or 4-HHE (25 µM) for 6 h. Relative mRNA expression of Mcp-1 was quantitated using
RT-qPCR. The results were normalized against 18S rRNA and expressed as fold increase
over control. (C) 4-HHE and 4-HNE content in VSMCs were measured using LC-MS/MS.
(D) p38, ERK, JNK and their phosphorylated forms, and β-actin were determined by
Western blotting. DHA (50 µM), EPA (50 µM) or 4-HHE (25 µM) were added for 10 min.
(E) Pretreatment with p38 kinase inhibitor (SB203580; 10 µM), ERK inhibitor (PD98059;
25 µM) or JNK inhibitor (SP600125; 10 µM) was performed for 30 min before BSA,
DHA, EPA or 4-HHE incubation. The results were normalized against 18S rRNA and
expressed as fold increase over corresponding control. (A) Values represent the mean ˘ SE
of four independent experiments (n = 9); (B) a single experiment (n = 3); (C) a single
experiment (n = 3); or (E) three independent experiments (n = 3–9). * P < 0.05, ** P < 0.01,
*** P < 0.001, compared with corresponding control.
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Figure 4. DHA-derived 4-HHE reduces cell viability through apoptosis in VSMCs. (A) 
VSMCs were treated with a high concentration of DHA (150 μM), EPA (150 μM) or 4-HHE 
(50 μM) for 24 h. Cell viability was determined by the MTT assay. Values are expressed as 
percentage of cell survival, and each value represents the mean ± SE of five experiments  
(n = 15). (B) Cleaved caspase-3 and β-actin were determined by Western blotting. DHA (150 
μM), EPA (150 μM) or 4-HHE (50 μM) were added for 6 h. * P <0.05, *** P < 0.001, 
compared with BSA control. 
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that DHA induced apoptosis in VSMCs or cancer cells through p38 MAPK activation at 24 hours 
[24,25]. Another report demonstrated that 4-HHE induced cytotoxic and negative effects on YPEN-1 
Figure 4. DHA-derived 4-HHE reduces cell viability through apoptosis in VSMCs.
(A) VSMCs were treated with a high concentration of DHA (150 µM), EPA (150 µM)
or 4-HHE (50 µM) for 24 h. Cell viability was determined b the MTT assay. Values
ar expressed as percentage of c ll survival, and ach value represents the m an ˘ SE of
five experiments (n = 15). (B) Cleaved caspase-3 and β-actin were determined by Western
blotting. DHA (150 µM), EPA (150 µM) or 4-HHE (50 µM) were added for 6 h. * P < .05,
*** P < 0.001, compared with BSA control.
4. Discussion
Our study has three important findings. First, DHA and 4-HHE, but not EPA, inhibited Mcp-1
expression in rat arterial strips. Second, DHA and 4-HHE inhibited cell survival by promoting apoptosis
in VSMCs. Third, DHA, EPA and 4-HHE stimulated Mcp-1 expression via oxidative stress, p38 and the
Keap1-Nrf2 pathway in VSMCs.
DHA and 4-HHE, but not EPA, inhibited Mcp-1 expression in rat arterial strips. Previous studies
have shown that n-3 PUFAs affect inflammation and plaque stability [22,23], which is consistent with
the inhibitory effect of DHA on Mcp-1 expression under ex vivo conditions in our study. In contrast, EPA
had almost no effect on Mcp-1 expression (Figure 1A). We assume this difference was the result of Nrf2
activation by 4-HHE, because we observed a similar difference between DHA and EPA in HUVECs,
which was explained by the generation of 4-HHE [10,11,14–16]. As expected, DHA preferentially
increased intracellular 4-HHE content in rat arterial strips compared with EPA (Figure 1C). In addition,
4-HHE directly inhibited Mcp-1 expression in rat arterial strips (Figure 1D). Although the molecular
mechanism underlying this phenomenon is not clear, 4-HHE may be a mediator of the anti-inflammatory
effect of DHA.
We also found that DHA and 4-HHE at a higher concentration and longer incubation inhibited cell
survival by promoting a optosis in VSMCs. In agreement with our study, previous rep rts have shown
that DHA induc d apoptosis in VSMCs or cancer cells through p38 MAPK activation at 24 h urs [24,25].
Another report demonstrated that 4-HHE induced cytotoxic and negative effects on YPEN-1 prostatic
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endothelial cells at 24 hours [26]. Because migration of transformed VSMCs is one of the main features
of atherosclerosis [27], 4-HHE-induced apoptosis, followed by macrophage clearance via MCP-1
expression may be beneficial. Conversely, apoptosis in advanced plaque lesions may be detrimental.
This discrepancy might explain the inconsistent effects of n-3 PUFAs on cardiovascular events in a
secondary prevention study [28].
Both DHA and EPA stimulated Mcp-1 expression in VSMCs. Our preliminary data suggest that
other fatty acids including palmitic and arachidonic acid also stimulate Mcp-1 expression. We speculate
that this was due to oxidative stress induced by fatty acids—known as lipotoxicity [29,30]—rather
than being an n-3 PUFA-specific effect. In addition to lipotoxicity, DHA preferentially degrades to
4-HHE via peroxidation. 4-HHE has an aldehyde residue that causes a Michael reaction with proteins,
forming protein adducts [13]. N-acetyl-L-cysteine—a known antioxidant—protected VSMCs from
4-HHE-induced Nrf2 action through the formation of 4-HHE-NAC adducts. Nrf2 siRNA inhibited the
4-HHE-induced Mcp-1 expression, suggesting that DHA stimulated Mcp-1—at least in part—through
the 4-HHE-Nrf2 pathway.
The opposite effects caused by DHA on Mcp-1 mRNA expression between arterial strips and
VSMCs were observed in this study. VSMCs were cultured in a different environment as compared
to arterial strips: culture media, growth factors, and monolayer. These biological factors may explain
the discrepancy between arterial strips and VSMCs. Other possibilities are that endothelial cells are a
major source of Mcp-1 mRNA and that endothelial cells induce smooth muscle cells to suppress Mcp-1
mRNA in response to DHA. To test this possibility, DHA-induced Mcp-1 expression were analyzed in
VSMCs with the condition media from rat aortic endothelial cells, and aortic strips without endothelial
cells. Our preliminary data suggest that DHA-induced Mcp-1 is not affected by endothelial cells.
DHA but not EPA produces 4-HHE in rat arterial strips and VSMCs. Previous reports from our group
and others have shown that the 4-HHE content or 4-HHE adducts increased after fish oil treatment in
heart, liver and other tissues [15,31,32]. Furthermore, previous reports have shown that plasma 4-HHE
levels increased following supplementation with DHA or fish-based diet intervention in humans [33,34].
The reason for the difference in 4-HHE generation between DHA and EPA is not clear; hence, further
experiments are necessary to elucidate this phenomenon.
Concentrations of EPA and DHA (25–150 µM) used in this study are similar to previous
studies [3,11,14,16]. These concentrations are relatively low compared to the reported concentrations
in human plasma (200–400 µM) [3]. As shown in Figure 4, high concentrations of DHA had a cytotoxic
effect compared to high concentrations of EPA. This phenomenon was consistent with a previous study
that showed DHA but not EPA had a profound growth inhibitory effect on HPV16 immortalized cells
but not on normal cells [35]. In addition, DHA has strong inhibitory effects on multiple cancer cell
lines [26]. We speculated that 4-HHE preferentially generated by DHA might explain the difference
between DHA and EPA.
There were some limitations in this study. First, we could not identify the molecular mechanism of
the DHA-induced Mcp-1 decrease in artery strips, although our data suggest that 4-HHE-induced Nrf2
activation may play a role. Second, the 4-HHE content measured was free 4-HHE. Because 4-HHE
generates 4-HHE adducts—especially with glutathione—the total 4-HHE content in the tissues may be
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higher. We incubated VSMCs with 4-HHE at 25 µM based on its ability to stimulate Hmox1. Third, the
clinical significance of the DHA-induced Mcp-1 expression is still not clear.
5. Conclusions
DHA had contrasting effects on Mcp-1 expression in vessels and VSMCs. We suggest a possible role
for Nrf2 activation by DHA-derived 4-HHE. Furthermore, 4-HHE derived from DHA decreased cell
viability by inducing apoptosis in VSMCs. These findings may explain the different effects of EPA and
DHA on vessels.
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